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Abstract
The aim of this study was to compare costs and socio-economic impact of tuberculosis (TB) for
patients diagnosed through active (ACF) and passive case finding (PCF) in Nepal. A longitudinal
costing survey was conducted in four districts of Nepal from April 2018 to October 2019. Costs
were collected using the WHO TB Patient Costs Survey at three time points: intensive phase of
treatment, continuation phase of treatment and at treatment completion. Direct and indirect costs
and socio-economic impact (poverty headcount, employment status and coping strategies) were
evaluated throughout the treatment. Prevalence of catastrophic costs was estimated using the
WHO threshold. Logistic regression and generalized estimating equation were used to evaluate
risk of incurring high costs, catastrophic costs and socio-economic impact of TB over time. A total
of 111 ACF and 110 PCF patients were included. ACF patients were more likely to have no educa-
tion (75% vs 57%, P¼ 0.006) and informal employment (42% vs 24%, P¼0.005) Compared with the
PCF group, ACF patients incurred lower costs during the pretreatment period (mean total cost:
US$55 vs US$87, P< 0.001) and during the pretreatment plus treatment periods (mean total direct
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costs: US$72 vs US$101, P< 0.001). Socio-economic impact was severe for both groups through-
out the whole treatment, with 32% of households incurring catastrophic costs. Catastrophic costs
were associated with ‘no education’ status [odds ratio¼ 2.53(95% confidence interval¼ 1.16–5.50)].
There is a severe and sustained socio-economic impact of TB on affected households in Nepal. The
community-based ACF approach mitigated costs and reached the most vulnerable patients.
Alongside ACF, social protection policies must be extended to achieve the zero catastrophic costs
milestone of the End TB strategy.
Keywords: Tuberculosis, case finding, costs, catastrophic costs, Nepal
Introduction
Tuberculosis (TB) kills more people each year than any other single
infectious disease and principally affects the most vulnerable popu-
lations in low- and middle-income countries (World Health
Organization, 2019). The socio-economic consequences of TB are
often severe, and many TB-affected households are pushed into ex-
treme poverty due to the high out-of-pocket expenditures and in-
come lost during the search for TB diagnosis and treatment.
Structural causes commonly found in developing countries, such as
seasonal economy, poor access to healthcare facilities and low edu-
cation, can also contribute to worsening the economic hardship
faced by TB-affected households (Whitehead and Dahlgren, 2007;
Barrett and Carter, 2013). The World Health Organization’s
(WHO) End TB strategy (World Health Organization, 2015b) has
established ambitious goals to advance towards TB elimination,
including zero catastrophic costs for TB affected households, to be
achieved by 2020. Catastrophic TB costs are defined by WHO as
total costs of TB diagnosis and care above 20% of the household’s
annual income (World Health Organization, 2015a). The latest
Global TB report published by the WHO in 2010 shows that the
zero catastrophic costs milestone will not be achieved by the end of
2020. National costing surveys conducted in 12 high burden coun-
tries have shown that the percentage of TB-affected families facing
catastrophic costs ranged from 27% in Kenya to 83% in Timor-
Leste for all forms of TB. As catastrophic cost is an important indi-
cator to estimate the economic burden of TB and evaluate access to
healthcare, the WHO has established a monitoring framework
including this indicator as essential to monitor beyond 2020. The or-
ganization has also recommended universal health coverage to im-
prove access to high-quality TB diagnosis and treatment and social
protection schemes as priority policies to achieve the zero cata-
strophic costs milestone (World Health Organization, 2020).
Another recommendation to monitor the progress towards the
zero catastrophic costs milestone is the implementation of patient
cost surveys (World Health Organization, 2019). Several countries
have now conducted national or local surveys by adopting cross-
sectional (Nhung et al., 2018) or longitudinal approaches (Foster
et al., 2015); addressing costs of TB and co-morbidities such as HIV/
AIDS (Mudzengi et al., 2017; de Siqueira Filha et al., 2018) and dia-
betes (Arnold et al., 2016); and comparing active case finding (ACF)
vs passive case finding (PCF) (Morishita et al., 2016; Gurung et al.,
2019; Muniyandi et al., 2020). Modelling studies have also been
developed to determine the impact of specific TB interventions on
patient costs (Verguet et al., 2017). However, evidence regarding
the impact of community-based ACF on patient costs using the
more detailed longitudinal approach is still lacking.
Nepal is one of the poorest countries in Asia with 15% of the
population classified as extremely poor (World Bank, 2018). The
2018–19 national TB prevalence survey in Nepal showed an inci-
dence rate of 245/100 000, which is much higher than previous esti-
mates (Government of Nepal et al., 2020). This means that less than
half (46%) of the incident TB cases in Nepal in 2019 (69 000) were
diagnosed or notified via the government system, with approximate-
ly 40 000 ‘missing’ cases occurring annually (Government of Nepal
et al., 2020). Strategies to reach these missing TB cases are urgently
needed. ACF (World Health Organization, 2013) reaching out into
communities to actively screen and diagnose people with TB is one
strategy to reduce this case notification gap, decrease morbidity and
mortality and interrupt community transmission.
The IMPACT TB was launched in 2017 to implement a
community-based ACF model in four districts of Nepal and to in-
crease the evidence for optimal ACF scale-up policies. Here, we re-
port the results of the cost analysis that compared costs and socio-
economic impact of TB in patients diagnosed through ACF with the
standard National TB Programme (NTP) PCF.
KEY MESSAGES
• The community-based active case finding (ACF) strategy reduced tuberculosis (TB) pretreatment cost for patients by 65% (ACF:
US$20; passive case finding: US$58).
• The ACF strategy reached the most vulnerable and disadvantaged population and can contribute to promoting equity of access to TB
services.
• The longitudinal costing survey evidenced an enduring and severe socio-economic impact in both groups. The unemployment rate
increased by 72% during the intensive phase of treatment, and patients continually reported food insecurity throughout treatment.
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Methods
Study design and setting
A longitudinal TB Patient Cost Survey was conducted between April
2018 and October 2019 in four districts of Nepal covering both
rural and urban areas, hilly and lowland Terai regions: Dhanusha
(population 754 777; 2.8% of the national population) and
Mahottari (population 627 580; 2.4% of the national population) in
Province 2, and Makwanpur (population 420 477; 1.6% of the na-
tional population) and Chitwan (population 579 984; 2.2% of the
national population) in Province 3. Makwanpur, Mahottari and
Chitwan districts are considered high burden TB districts, i.e. case
notification rate (CNR) >120, and Dhanusha is classified as me-
dium TB burden district, i.e. CNR between 75 and 120. These dis-
tricts reported 2061 TB cases in 2018, which accounts for 11% of
all reported TB cases in Nepal (Ministry of Health & Population
et al., 2018).
Sample size calculation and sampling
At the time of study design, there were no studies comparing ACF
and PCF incurred patient costs on which to base an effect size esti-
mate. Therefore, we took a pragmatic approach and sample size was
based upon previous TB patient costing surveys in other countries
that showed a sample of 100 patients is sufficient to capture the
spectrum of TB patient costs incurred (Ukwaja et al., 2012).
Allowing for an expected attrition rate of 20% in the study sites,
121 patients were therefore recruited for each study arm (ACF and
PCF). TB patients diagnosed through ACF and PCF were registered
at IMPACT TB database and at the treatment registers at Directly
Observed Treatment Short-course (DOTS) centres, respectively. A
research associate checked the list of patients diagnosed in both
databases monthly and consecutively selected participants until
reaching the target sample size in each arm. Patients were recruited
from April 2018 to January 2019.
Inclusion criteria
Adults, 18 years old, with laboratory bacteriological confirmed
pulmonary TB (new, retreatment or relapse), resident of Nepal, with
written informed consent provided were eligible for this study.
Drug-resistant TB patients were excluded from this study due to
time and budget constraints.
Interventions
PCF is the current practice implemented by the NTP in Nepal .
Symptomatic individuals seek healthcare by self-presentation at
healthcare facilities, which includes a network of health posts, pri-
mary health centres and government district hospitals. PCF pathway
includes (1) patients are aware of their symptoms and access health
facilities, (2) patients are evaluated by health workers who recognize
the symptoms of TB and (3) patients are referred to diagnostic
centres to collect sputum sample and perform a TB test (World
Health Organization, 2013). In Nepal, sputum smear microscopy is
the standard diagnostic test within the NTP, with GeneXepert avail-
able in some centres and currently reserved for priority groups. The
NTP is prioritizing the scale-up of GeneXpert testing (Government
of Nepal et al., 2017).
Full details of the community-based ACF model applied are
given elsewhere (Gurung et al., 2019). A brief description is given
below.
ACF was implemented through a community-based approach,
identifying presumptive TB cases via symptom screening of social
contacts of all TB index cases in the district. In addition, TB camps
were implemented in remote communities. Household contacts of
TB index cases were screened in these districts by a separate Global
Fund supported intervention. The IMPACT TB study applied smear
microscopy for TB testing in Mahottari and Makwanpur and
GeneXpert MTB/RIF in Chitwan and Dhanusha.
Index TB patients were identified at the government health facili-
ties and were contacted to collect information about their social
contacts. After consent of the index patient, community health
workers (CHW) scheduled a visit to the social contacts to perform
symptom screening (cough, fever, night sweats or weight loss).
Presumptive cases were invited to undergo TB testing.
TB camps were performed in areas with a high number of TB
cases notified and remote areas with no healthcare access and infor-
mal settlements. Door-to-door symptom screening by CHW identi-
fied presumptive cases for TB testing at the camp.
All positive TB cases were enrolled on standard TB treatment at
the nearest government DOTS facility.
Data collection tool
The WHO TB Patient Costs Survey (KNCV Tuberculosis
Foundation, World Health Organization and Japan Anti-
Tuberculosis Association, 2008) was adapted, translated into Nepali
and piloted in 16 patients prior to use in this study. The survey col-
lected socio-economic data, direct medical costs (e.g. drugs, tests,
medical fees), direct non-medical costs (e.g. transportation, accom-
modation and food) and indirect costs (e.g. lost time and income
loss) and information on the social and economic impact of TB.
After piloting, the survey was used by trained CHWs to conduct
paper-based interviews at the location preferred by the patient, usu-
ally the residence of the patient or at a health facility. Interviewers
followed a standard operating procedure manual developed by the
project team. Completed questionnaires were then reviewed by a re-
search associate and district program coordinators. CHWs were
advised to contact patients to clarify or correct any missing or in-
complete information. Participants were compensated for their time
(60 minutes) with 500 Nepalese rupees (NPR) (US$4.5) for each
interview.
Patient costs, time horizon
Patient costs were collected at three time points. The first interview
was conducted during the intensive phase (between 2 weeks and 2
months of treatment initiation) and collected data on costs incurred
during pre-TB diagnosis (since the onset of TB symptoms) and treat-
ment period until the date of the interview. Two subsequent inter-
views collected information on costs incurred during TB treatment,
covering the time since the preceding interview. The second inter-
view was applied during the continuation phase of treatment (be-
tween 3 months and 4 months) and the third at the end of treatment
(sixth month of treatment). Therefore, costs incurred during TB ill-
ness from the time of symptom onset (self-reported by patients) to
the time of TB treatment completion were calculated.
Data entry and analysis
Questionnaires were entered by trained study staff into a dedicated
study database designed by IMPACT TB consortium partners.
Socio-economic profile
The living standard was assessed using the indicators recommended
by the government of Nepal to evaluate multidimensional poverty,
i.e. education level, and proportion of patients included in the study
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with access to electricity, drinking water, sanitation and asset own-
ership (Government of Nepal and Oxford Poverty and Human
Development Initiative, 2018).
Patient costs
Mean costs with 95% confidence intervals (CIs) and median costs
with the interquartile range were estimated by cost type (direct med-
ical, direct non-medical and indirect costs) and by treatment period
(pretreatment and treatment). Total costs were calculated by sum-
ming all costs incurred during the pretreatment and treatment peri-
ods. Direct costs were calculated by summing all costs in each
category (medical and non-medical). Indirect costs comprised lost
income and lost time seeking diagnosis and care. Lost income was
calculated using the human capital approach (Government of Nepal
et al., 2018), applying self-reported length of time absent from
work, 2018 Nepali monthly minimum wage (US$121.05), the la-
bour force participation rate (49%) and unemployment rate
(1.2%)(World Bank, 2018). Lost time was converted to a monetary
value by applying hourly (US$0.62) and daily (US$4.67) minimum
wages (Government of Nepal et al., 2018). Costs were collected in
the local currency, NPR, and were converted to US$ applying the
average exchange rate from OANDA during the data collection
period (NPR 1¼US$0.009) (https://www1.oanda.com/) (OANDA,
2018). Participants who could not be located for the second or third
interviews were considered lost to follow-up and were excluded
from the analysis.
To evaluate uncertainty in costs, one-way sensitivity analysis
was performed. Total costs were calculated by varying direct medic-
al, non-medical and indirect costs according to the upper and lower
limit of their CIs (Taylor, 2009).
Socio-economic impact
Income changes, employment status, poverty headcount (World
Bank, 2019), self-reported social impact (food insecurity, social ex-
clusion and others), self-reported sense of relative economic status
(e.g. feeling poorer) and use of coping strategies were analysed
throughout the treatment.
Catastrophic costs
The prevalence of households with catastrophic costs was deter-
mined for the WHO threshold for TB (total cost >20% of the an-
nual household income). Catastrophic costs were calculated
according to the annual household income self-reported before the
onset of TB. Catastrophic costs and pretreatment costs were not cal-
culated for retreatment and relapse TB cases as we were not able to
accurately determine pretreatment costs for this group due to the
length of time elapsed between initial TB diagnosis and the
interview.
Statistical analysis
Data analysis was performed using Stata version 15 (STATA,
Statacorp, TX, USA). Frequency distributions and descriptive statis-
tics such as mean/median were calculated. Chained multiple imput-
ation (Royston, 2005) was used to estimate missing costs data
(Supplementary Table S1). Ten multiple imputed data sets with five
iterations were generated. The variables gender, age, type of pro-
vider, district and ACF/PCF were included in the imputation model.
Chi-square and Fischer’s exact test were applied to test differences
in proportions of categorical variables. Wilcoxon rank-sum test was
used to compare costs between ACF and PCF. P-values 0.05 were
considered statistically significant.
The association between catastrophic costs and high costs, i.e.
costs above the 75th quartile incurred during the pretreatment and
treatment periods (de Cuevas et al., 2016), and adjusted by baseline
characteristics (i.e. ACF/PCF, sex, age, education level, employment
status and patient income) was explored through multiple logistic
regression. Odds ratios (ORs) with 95% CIs were estimated.
We fitted an interaction term between ACF/PCF and treatment
phase using a generalized estimating equation (Zeger and Liang,
1986) to evaluate the effect of ACF on the socio-economic charac-
teristics throughout TB treatment: unemployment, food insecurity,
social exclusions, to be poorer/much poorer, coping strategies, pa-
tient and household incomes and poverty headcount.
We used the CHEERS (Husereau et al., 2013) checklist when
writing our report.
Ethical
The study was approved by the ethical committees of the authors’
institutes. All participants received a written Patient Information
Sheet and an oral explanation about the study. Written informed
consent was obtained before each interview.
Results
A total of 243 patients were recruited for the study. No eligible pa-
tient declined participation. Twenty-two patients (9%) were lost to
follow-up, 20 patients were not located for the second interview and
two for the third interview. Therefore, 221 patients completed the
three interviews and were included in the final analysis: 111 ACF
and 110 PCF. No deaths occurred among the included participants
(Supplementary Figure S1). Included and excluded patients had
similar socio-economic characteristics at baseline, except for income
and ownership of bicycle (Supplementary Table S2).
Socio-economic profile
Most participants were male (n¼147/221; 67%), in line with the
gender ratio of notified TB cases in Nepal. ACF patients were more
likely than PCF patients to be manual workers (28% vs 14%,
P¼0.015), have a lower level of education, with significantly more
individuals in the no-education category (75% vs 57%, P¼0.013)
and significantly fewer having completed secondary school (9% vs
21%, P¼0.013). Ownership of a mobile phone and television was
less frequent among ACF patients compared with PCF patients
(88% vs 95%, P¼0.044 and 49% vs 63%, P¼0.042, respectively).
Source of drinking water, type of toilet facility and availability of
electricity in the home were similar among the ACF and PCF groups
(Table 1).
Treatment characteristics
Most patients included in the study were new TB cases (214/221,
97%). During the pretreatment period, ACF patients reported less
hospitalization (6% vs 19%, P¼0.004) and fewer visits to health
providers (median number of visits¼2.8 vs 4.6, P<0.001). ACF
patients were less likely than PCF patients to visit public sector
healthcare facilities (47% vs 55%, P¼0.026) and more likely to ac-
cess other types of health providers in seeking a diagnosis, which
includes local NGOs and informal providers such as pharmacists
and traditional healers (25% vs 19%, P¼0.044). During the treat-
ment period, the number of visits and type of health facilities visited
were similar for both groups (Table 2).
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Patient costs
During the pretreatment period, ACF patients incurred lower total
costs (mean cost, US$56 vs US$87, P<0.001). When analysed by
cost category, ACF patients also had significantly lower direct med-
ical (mean cost, US$41 vs US$53, P<0.001), non-medical (mean
cost, US$7 vs US$18, P<0.001) and indirect/time loss costs (mean
cost, US$8 vs US$15, P<0.001).
During the treatment period, the costs incurred by ACF and PCF
patients were similar. The total costs incurred, including both pre-
treatment and treatment periods, was lower for ACF patients for
direct medical (mean cost, US$58 vs US$74, P¼0.009), non-
medical (mean cost, US$14 vs US$28, P<0.001) and total direct
cost (mean cost, US$72 vs US$101, P<0.001) (Table 3).
The multiple logistic regression showed that compared with PCF
patients, ACF patients were 62% less likely to incur high total costs
[adjusted OR¼0.38 (95% CI¼0.19–0.77)] (Supplementary Table
S3).
The one-way sensitivity analysis showed that in both ACF and
PCF, indirect costs were the parameter with highest uncertainty. For
ACF patients, the total cost varied from US$208 to US$257 and for
PCF the variation was from US$248 to US$312 (Supplementary
Figure S2).
Socio-economic impact and catastrophic costs
The proportion of patients unemployed increased compared with
pretreatment employment status. This was true for both ACF and
PCF patients (71% increase for ACF and 75% for PCF) (Table 4).
ACF patients employed in formal jobs were less likely to change
their employment status when compared with PCF (20% reduction
Table 1 Baseline socio-economic characteristics of TB patients diagnosed through ACF and PCF. Nepal 2019
Patient features ACF, N¼ 111 PCF, N¼ 110 Pooled sample, N¼ 221 P-valuea
Sex, N (%)
Male 71 (64) 76 (69) 147 (67) 0.42
Age, mean (SD) 50 (15) 46 (17) 48 (16) 0.057
Completed education, N
(%)b
No education 83 (75) 63 (57) 146 (66) 0.006*
Basic school 18 (16) 24 (22) 42 (19) 0.29
Secondary school 10 (9) 23 (21) 33 (15) 0.01*
Occupation, N (%)
Farmer 23 (21) 16 (14) 39 (18) 0.23
Manual labour 31 (28) 16 (14) 47 (21) 0.01*
Unemployed 31 (28) 29 (26) 60 (27) 0.79
Others 26 (23) 49 (44) 75 (34) 0.001*
Patient income quartile
Poorest 43 (39) 51 (46) 94 (43) 0.25
Moderately poor 13 (12) 6 (5) 19 (9) 0.10
Average 29 (26) 25 (23) 54 (24) 0.56
Wealthiest 26 (23) 28 (25) 54 (24) 0.72
Household income quartile
Poorest 39 (35) 30 (27) 69 (31) 0.21
Moderately poor 21 (19) 23 (21) 44 (20) 0.71
Average 29 (26) 29 (26) 58 (26) 0.97
Wealthiest 22 (20) 28 (25) 50 (23) 0.32
Source of drinking water, N
(%)
Piped 34 (31) 40 (36) 74 (33) 0.37
Others 77 (69) 70 (64) 147 (67)
Toilet facilities, N (%)c
No toilets 25 (23) 16 (15) 41 (19) 0.13
Public sewage 1 (1) 5 (5) 6 (3) 0.10
Others 85 (77) 88 (81) 173 (79) 0.45
Electricity, N (%) 98 (91) 104 (94) 202 (93) 0.28
Assets, N (%)
Mobile/phone 95 (88) 105 (95) 200 (92) 0.044*
Refrigerator 11 (10) 20 (18) 31 (14) 0.09
Television 53 (49) 69 (63) 122 (56) 0.042*
Radio 31 (29) 45 (41) 76 (35) 0.059
Bicycle 72 (67) 72 (65) 144 (66) 0.85
Motorbike 18 (17) 26 (24) 44 (20) 0.20
Livestock 80 (74) 76 (69) 156 (71) 0.41
aChi-square and Fischer’s exact, Wilcoxon rank sum.
bBasic schools ¼ primary level/lower secondary level (1–8 years of education).
cOne missing data.
*Statistically significant
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in formal employment for ACF compared with 77% reduction for
PCF) (Figure 1a).
Food insecurity was reported by over a third of households and
was the social impact most frequently reported at all stages of TB
treatment by both ACF patients (38%, 43% and 33%) and PCF
patients (33%, 31% and 30%) (Figure 1b). ACF patients were more
likely to report food insecurity [OR¼1.70 (95% CI¼0.98–2.95)]
and social exclusion [OR¼2.71 (95% CI¼1.01–7.26)] during the
continuation phase when compared with PCF patients (Table 4).
Economically, over half of all patients reported feeling ‘poorer’ or
‘much poorer’, with no patients feeling ‘richer’ (Figure 1c).
The frequency and pattern of utilization of coping strategies was
similar in the two groups in all treatment phases (Table 4).
Approximately a quarter of patients reported using coping strat-
egies, i.e. selling essential assets or taking out loans, during the in-
tensive phase of treatment (22% for ACF and 25% for PCF,
P¼0.61) and the frequency had reduced by the continuation phase
(13% for ACF and 10% for PCF, P¼0.42) and treatment comple-
tion (7% for ACF and 9% for PCF, P¼0.61) (Figure 1d). The
prevalence of catastrophic costs was similar for ACF and PCF (31%
vs 32%, P¼0.91) and more frequent in the poorest households
(Figure 1e). ‘No education’ was associated with catastrophic costs
[adjusted OR¼2.84 (95% CI ¼ 1.34–6.00)] (Supplementary Table
S4).
Patient income, household income and poverty headcount trends
were similar for ACF and PCF throughout treatment (Table 4). The
median patient income decreased to US$0 during the intensive phase
for both groups and patients did not recover their pre-TB income by
the end of treatment. The same pattern was observed for household
income. In the intensive phase, the poverty headcount increased
from 40% to 77% for ACF (92% increase) and from 46% to 79%
for PCF (72% increase). The poverty headcount remained high until
the end of treatment for both groups (Figure 1f).
Discussion
The economic consequences of TB disease for affected families can
be devastating. Our data showed that the mean total costs incurred
were US$256 in a country with a Gross National Income per capita
of US$970 in 2018 (World Bank, 2018). Three quarters of TB
patients experienced extreme poverty in the intensive phase of treat-
ment. Importantly, we have shown that ACF can be an effective
strategy to both reach the most vulnerable patient groups and reduce
the economic impact.
ACF patients diagnosed under the community-based strategy
were more likely to be those with no formal education, working in
the informal sector and in the lowest socio-economic groups. These
are the patients failed by the standard model of NTPs using PCF (Li
et al., 2013; Ukwaja et al., 2013).
These findings add to the body of evidence showing that ACF
strategies can increase equity of access to TB services, particularly
among the most vulnerable and disadvantaged populations, and
bring us closer to achieving the Declaration of Rights for TB
Patients (Yassin et al., 2013; The Global Fund, 2018; Saunders
Table 2 Treatment characteristics of TB patients diagnosed through ACF and PCF (Nepal, 2019)
Characteristics ACF, N¼ 111 PCF, N¼ 110 Pooled sample, N¼ 221 P-valuea
Treatment status, N (%)
New 105 (95) 109 (99) 214 (97) 0.056
Retreatment and relapse 6 (5) 1 (1) 7 (3)
HIV status, N (%)
Positive 1 (1) 1 (1) 2 (1) 0.75
Negative 76 (68) 77 (70) 153 (69) 0.80
Unknown 34 (31) 32 (29) 66 (30) 0.99
Number of weeks between onset of TB symptoms
and treatment initiation,b median (IQR)
7 (3–13) 6 (4–12) 6 (3–13) 0.87
Hospitalization pretreatment,b N (%)
Yes 7 (6) 21 (19) 28 (13) 0.004*
Hospitalization treatment, N (%)
Yes 2 (2) 1 (1) 3 (1) 0.57
Visits to health providers, pretreatmentb ACF, N¼ 300c PCF, N¼ 498c Pooled sample, N¼ 798c P-valuea
Number of visits to health providers, mean (SD) 2.8 (1.8) 4.6 (2.3) 3.7 (2.2) <0.001*
Type of service visited,d N (%)
Public health centres/hospitals 140 (47) 273 (55) 413 (52) 0.026*
Private clinics/hospitals 84 (28) 129 (26) 213 (27) 0.52
Otherse 76 (25) 96 (19) 172 (21) 0.044*
Visits to health providers, treatmentf ACF, N¼ 249c PCF, N¼ 237c Pooled sample, N¼ 486c P-valuea
Number of visits to health providers, mean (SD) 2.2 (1.2) 2.2 (1.3) 2.2 (1.3) 0.70
Type of service visited,g N (%)
Public health centres/hospitals 208 (86) 203 (87) 411 (87) 0.70
Private clinics/hospitals 9 (4) 17 (7) 26 (5) 0.09
Othersd 21 (10) 12 (5) 36 (8) 0.05
aChi-square, Fischer’s exact and Wilcoxon rank sum.
bSix ACF and one PCF relapse cases excluded from the analysis.
cN is the total number of visits to health providers.
dOne PCF visit missed.
eNGOs, and informal providers such as pharmacists and traditional healers.
fEmergency and inpatient care.
gThirteen missing data.
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et al., 2019). Studies conducted in India and Nigeria also found
higher vulnerability among ACF patients when compared with PCF,
such as lower education level, higher rates of unemployment, older
patients and longer duration of symptoms (Abdurrahman et al.,
2017; Shewade et al., 2018).
We also demonstrated that ACF was associated with significant-
ly lower patient costs during the pretreatment period (mean total
pretreatment costs US$56 for ACF group vs US$87 for PCF group;
P<0.001). Cost surveys conducted in Nepal and Cambodia found
similar results as ours (Morishita et al., 2016; Gurung et al., 2019).
Although the number of weeks between the first TB symptoms and
treatment initiation was similar between ACF and PCF, ACF patient
costs were mitigated by the reduction in the number of visits to
health facilities during the pretreatment period and, consequently,
reduction in direct cost, such as transportation, unnecessary medica-
tion and tests in private services, and time lost waiting for
Figure 1 Socio-economic impact of TB in patients diagnosed through ACF and PCF according to the treatment phase (Nepal, 2019). (a) Employment status; (b) so-
cial impact; (c) financial impact; (d) coping strategies; (e) prevalence of catastrophic cost according to income quartile; (f) poverty headcount (%), median patient
and household incomes (US$).
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appointments and traveling to and from healthcare facilities. ACF
would not be expected to substantially influence the patient costs
once on treatment, since both patient groups were enrolled into and
treated via the government DOTS programme.
ACF was associated with lower total costs [adjusted OR¼0.38
(95% CI¼0.19–0.77)]. However, the prevalence of catastrophic
costs was similar for both ACF and PCF patients, reflecting the
lower initial socio-economic status of the ACF group. Also, our data
showed that catastrophic costs were associated with ‘no education’
status, which was more frequent in ACF patients. Other studies
have found catastrophic costs associated with number of symptoms,
number of healthcare visits and use of nutritional supplements in
Figure 1 Continued
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South Africa (Foster et al., 2015); alcohol use and PCF in India
(Muniyandi et al., 2020); and previous TB treatment and job loss in
Indonesia (Fuady et al., 2018). Our findings strengthen the evidence
that while ACF may reduce household expenditure, this strategy
needs to be implemented alongside social protection policies to pro-
tect TB patients from financial hardship and to achieve the zero
catastrophic costs target in by the End TB strategy (World Health
Organization, 2015b).
The longitudinal design identified a similarly severe pattern of
socio-economic impact throughout the treatment for both ACF and
PCF groups. The disease caused major socio-economic consequences
for patients during the intensive phase. These included increased un-
employment, a drastic reduction in income, high rates of food inse-
curity, utilization of coping strategies and falling into extreme
poverty. Patients continued to report high rates of financial and so-
cial impact at treatment completion and were not able to recover the
income to the levels earned before the onset of TB symptoms. These
findings indicate that TB triggered the medical poverty trap mechan-
ism, which reinforces the poverty cycle and can persist for genera-
tions (Whitehead and Dahlgren, 2007; Barrett and Carter, 2013;
Wingfield et al., 2014). Further studies adopting a longer follow-up
are needed to evaluate the socio-economic impact post-TB
treatment.
One of the limitations of our study is recall bias which may have
affected the accurate estimation of costs and catastrophic cost due
to the long interval between the interviews. The literature has shown
that recall bias particularly affects the estimates of indirect costs, in-
come lost in developing countries (World Health Organization,
2017; Stracker et al., 2019). The same is true in Nepal, where the
majority of TB patients are employed in the informal market or in
seasonal jobs that do not provide regular salaries or payslips (World
Bank, 2018). Also, the prevalence of catastrophic costs by using self-
reported income can be underestimated when compared with meth-
ods such as the asset linking approach or income estimated using the
national average (Sweeney et al., 2018).
The IMPACT TB costing survey was the first longitudinal survey
comparing ACF and PCF strategies in Nepal. The study design
allowed the investigation of the socio-economic impact of TB
throughout the whole treatment. Another advantage of this ap-
proach is the continuous collection of costing data with no extrapo-
lation techniques (WHO, 2017) applied, which will increase the
accuracy of estimates compared with the cross-sectional method-
ology. Another limitation of this study was the missing pretreatment
costs for relapse and retreatment patients with possible underestima-
tion of the total cost for ACF as this intervention had more patients
in this treatment category (6 ACF vs 1 PCF). However, a cross-
sectional survey conducted in Nepal indicated that PCF patients
were more likely to be affected by memory bias and underestimate
costs for pretreatment and intensive phase. A sensitivity analysis
comparing costs reported by ACF and PCF patients interviewed
within and after 1 month of treatment initiation found that PCF
patients reported lower median total costs when interviewed after 1
month after starting treatment during the pretreatment period(-
1 month: US$ 365.9; >1 month: US$ 128.5; P¼0.007), intensive
phase of treatment (<1 month: US$ 190.4; >1 month: US$ 67.6;
P¼0.004) and total costs estimates (<1 month: US$ 556.3;
>1 month: US$ 232.3, P¼0.002). No difference in costs was
reported for ACF patients interviewed within or after 1 month of
treatment initiation (Gurung et al., 2019). Therefore, the missing
cost in the pretreatment period for relapse and retreatment patients
is unlikely to have affected the differences in total costs between
ACF and PCF found in our survey.
ACF has been sporadically implemented in Nepal through sev-
eral organizations and using different approaches (Stop TB
Partnership and Birat Nepal Medical Trust, 2015; The Global Fund,
2018). However, to achieve a comprehensive and sustained imple-
mentation of efficient ACF models, some priority actions must be in
place. These actions must consider the limited health system resour-
ces and the complex geographical features of Nepal. Improvements
to human resource training and retention, an efficient quality con-
trol and logistics system to support diagnostic centres and reduction
of import duties on advanced molecular TB diagnostic tests such as
GeneXpert (Siqueira et al., 2019) would facilitate scale-up of ACF.
The use of innovative technologies, such as drones to collect sputum
sample and deliver TB medications, will be crucial to address chal-
lenges in sample transportation and comprehensively reach vulner-
able communities in hard to reach areas (Pudasaini, 2019; Birat
Nepal Medical Trust, 2020). Improved public–private linkages will
also be essential to improve patient access to high-quality TB diag-
nosis and treatment and to bring ACF to the healthcare facility level
(Government of Nepal et al., 2016). From the NTP perspective, an
efficient allocation of human and financial resources and improve-
ment of existing diagnostic centres are essential to successfully scale-
up ACF in Nepal (Ministry of Health & Population et al., 2018).
To break the poverty cycle among TB patients, alleviation pro-
grammes such as cash transfer, nutritional support and livelihood re-
habilitation schemes must be accessible to patients from diagnosis
and work in synergy with government scale-up initiatives under the
SDG drive for Universal Health Coverage.
Conclusions
The community-based ACF model reached the most vulnerable
patients and significantly reduced patient costs in the pretreatment
phase. However, patients in both the ACF and PCF groups reported
severe and enduring socio-economic consequences. Therefore, poli-
cies including social protection must be implemented to reach the
End TB strategy goals.
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